US Press Releases

Interim analysis of the Phase 3 PUNCH™ CD3-Open-Label Study (OLS) showed positive efficacy and consistent safety with RBX2660 for up…

RBX2660 pivotal Phase 3 trial successfully met the primary endpoint; data presented today at Digestive Disease Week® (DDW) RBX2660 is…

For the first time ever, Ferring and Rebiotix, a Ferring Company, will present landmark Phase 3 efficacy and safety data…

Teigen alongside RESOLVE: The National Infertility Association and Ferring Pharmaceuticals aim to change and amplify the fertility conversation by launching…

Parsippany, NJ – December 18, 2020 – Beginning January 1, 2021, Ferring Pharmaceuticals will gain preferred access through CVS Health…

CDC defines Clostridioides difficile (C. diff) infection as a significant healthcare burden to patients and physicians, labeling C. diff as…

Ferring and Rebiotix, a Ferring Company, will present two oral abstracts describing translational studies of investigational microbiome-based therapeutics RBX2660 and…

Ferring will deliver 11 presentations at the virtual congress; including six oral presentations The new data being presented further underscores…

FOR IMMEDIATE RELEASE – Parsippany, NJ – August 5, 2020– Ferring Pharmaceuticals US is voluntarily recalling all lots on the…

ORTIKOS is available in one convenient pill in two dosage strengths (9mg, 6mg) for the treatment of mild to moderate…